about
Novel mouse hemostasis model for real-time determination of bleeding time and hemostatic plug composition.Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets.High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system.RNA aptamers as reversible antagonists of coagulation factor IXa.Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV.Platelet activation in patients with thrombotic thrombocytopenic purpura.An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinaseThe use of recombinant factor VIIa in the treatment of bleeding disorders.Low intensity laser therapy speeds wound healing in hemophilia by enhancing platelet procoagulant activity.Cystamine preparations exhibit anticoagulant activityCoagulation 2006: a modern view of hemostasis.Major burn injury is not associated with acute traumatic coagulopathy.Soluble phosphatidylserine binds to two sites on human factor IXa in a Ca2+ dependent fashion to specifically regulate structure and activityCurrent concepts of hemostasis: implications for therapy.Potent anticoagulant aptamer directed against factor IXa blocks macromolecular substrate interaction.Recombinant activated factor VII and the anaesthetist.The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking.Platelet activation and its patient-specific consequences.A novel one-step purification of mouse factor IX.Further understanding of recombinant activated factor VII mode of action.Dysregulation of hemostasis by cancer.Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice.What is wrong with the allosteric disulfide bond hypothesis?Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease.FVIIa as used pharmacologically is not TF dependent in hemophilia B miceWound healing in hemophilia B mice and low tissue factor mice.Wound healing in haemophilia--breaking the vicious cycle.Studies on the mechanism of action of the aptamer BAX499, an inhibitor of tissue factor pathway inhibitor.A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity.Reversing targeted oral anticoagulants.Single synonymous mutation in factor IX alters protein properties and underlies haemophilia B.Characterization of IXINITY® (Trenonacog Alfa), a Recombinant Factor IX with Primary Sequence Corresponding to the Threonine-148 Polymorph.A mouse bleeding model to study oral anticoagulants.Thrombin generation and cell-dependent hypercoagulability in sickle cell disease.An activated factor VII variant with enhanced tissue factor-independent activity speeds wound healing in a mouse hemophilia B model.Coated platelets and severe haemophilia A bleeding phenotype: Is there a connection?Anticoagulation increases alveolar hemorrhage in mice infected with influenza A.Deencryption of cellular tissue factor is independent of its cytoplasmic domain.Structure/function analyses of recombinant variants of human factor Xa: factor Xa incorporation into prothrombinase on the thrombin-activated platelet surface is not mimicked by synthetic phospholipid vesicles.Adding some muscle to blood coagulation.
P50
Q27348034-4C4306C6-48F3-4627-B13F-88F95C1F5AE2Q31117459-0A095A8B-49A9-4B64-BB42-FA34A2A4159BQ33338284-C6F481C8-2687-4044-9942-AEC6C6859AB0Q33344114-3DDE8ED8-FF89-456B-947A-BBD285821E42Q33479306-D5EBBC69-2136-41E2-9B32-14D39E2D5D7CQ33489187-01BF9E45-78A3-4D8F-B87A-484922F3A882Q33519836-9C7DD804-8D42-4097-BBF8-6F73AC66CFB5Q34343186-AB3C0340-1911-4B66-94DB-81B968917473Q34375477-352983B4-34D5-4043-BBDA-9A8F99E8D7E6Q34473794-F79F259E-1039-4081-8947-F0E02E85D837Q34606940-963581E3-8DEC-4110-93E7-851C437E6490Q35125869-E250D397-3D5D-40C6-A6DA-8424A447C47FQ35198502-2A0C797B-F706-444E-AF59-B2E968A8683BQ35756132-D25D9B11-53E9-40A3-806F-E7110FC2FB89Q35921730-2B1D5894-457E-4AE9-A408-6F2CCEA50ED9Q36313315-1CD7F1DD-C58F-4FDE-9032-A0D9C80A90B1Q36849029-7AFEA390-B148-4D86-98FA-0E0D3CB2D121Q36976150-73B38833-0BAC-4049-93A6-EDA6AA32B80AQ37031645-03E9139C-65C4-475A-BD2A-F35C95155A17Q37188033-450FA31E-EE69-469C-93E1-8A4C9F975E82Q37450924-1091CF05-CD91-4210-81D7-565F1D59E5E5Q37623821-36607FBC-A504-46DF-A8B8-9A912EE9D5EAQ37634818-FD09C9DE-D9AE-4158-AFE0-D2A3B8C85450Q37636986-D74BDD43-1A48-4D9E-8D46-992D65125A00Q37636989-2860926B-C226-4E36-80A7-D94C41B0EA04Q37695429-D4B1B7EB-56C1-4EA3-B051-D76BEB03F45BQ37768479-01B47091-F777-43E4-B3CF-224AFD9096F3Q38324801-D9106628-3E5D-459D-A23A-93CF500AE864Q38327215-3F34DDC0-A2AE-477B-B0F3-B29F02B83BACQ38361803-E5DA12F6-4898-4F58-8001-48AA732C4826Q38779043-2D7EEDE1-73DE-4928-BEF3-7DDF1AD6C02EQ38796239-C3F25038-2144-4984-95E0-B65D85E04023Q39372785-5BBC3C0F-D8C3-4D77-8BBF-386BEF93A8F8Q39588275-54FC9983-60FA-44F2-AD3E-31CE8A4A6312Q39940714-F27274F3-0053-4E29-BCAC-905EEB6A1419Q40329444-13675F07-D8FF-4B9B-8338-AF521152C479Q40399798-9C733BC1-D2DE-4728-9B93-6769564100DEQ40876692-107BAA7C-EA7F-4DFA-B5B9-44FCE06BAC5CQ41043564-8E7794F6-0DD3-4E21-B29F-6C684CF7CE31Q41363473-24503E6E-093D-4904-8C31-3FC188923B1E
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Dougald M. Monroe
@ast
Dougald M. Monroe
@en
Dougald M. Monroe
@es
Dougald M. Monroe
@nl
Dougald M. Monroe
@sl
type
label
Dougald M. Monroe
@ast
Dougald M. Monroe
@en
Dougald M. Monroe
@es
Dougald M. Monroe
@nl
Dougald M. Monroe
@sl
prefLabel
Dougald M. Monroe
@ast
Dougald M. Monroe
@en
Dougald M. Monroe
@es
Dougald M. Monroe
@nl
Dougald M. Monroe
@sl
P106
P1153
35553442200
P21
P31
P496
0000-0002-0493-2943